AU2014321456B2 - Combination drug therapy - Google Patents

Combination drug therapy Download PDF

Info

Publication number
AU2014321456B2
AU2014321456B2 AU2014321456A AU2014321456A AU2014321456B2 AU 2014321456 B2 AU2014321456 B2 AU 2014321456B2 AU 2014321456 A AU2014321456 A AU 2014321456A AU 2014321456 A AU2014321456 A AU 2014321456A AU 2014321456 B2 AU2014321456 B2 AU 2014321456B2
Authority
AU
Australia
Prior art keywords
cancer
compound
methyl
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014321456A
Other languages
English (en)
Other versions
AU2014321456A1 (en
Inventor
Kurtis Earl Bachman
Samuel Charles BLACKMAN
Joel GRESHOCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2014321456A1 publication Critical patent/AU2014321456A1/en
Application granted granted Critical
Publication of AU2014321456B2 publication Critical patent/AU2014321456B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2014321456A 2013-09-19 2014-09-16 Combination drug therapy Ceased AU2014321456B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361879895P 2013-09-19 2013-09-19
US61/879,895 2013-09-19
PCT/US2014/055816 WO2015042029A1 (en) 2013-09-19 2014-09-16 Combination drug therapy

Publications (2)

Publication Number Publication Date
AU2014321456A1 AU2014321456A1 (en) 2016-03-10
AU2014321456B2 true AU2014321456B2 (en) 2018-05-24

Family

ID=52689320

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014321456A Ceased AU2014321456B2 (en) 2013-09-19 2014-09-16 Combination drug therapy

Country Status (10)

Country Link
US (1) US20160228446A1 (enExample)
EP (1) EP3046556A4 (enExample)
JP (3) JP6346944B2 (enExample)
KR (1) KR20160055911A (enExample)
CN (1) CN105530934A (enExample)
AU (1) AU2014321456B2 (enExample)
BR (1) BR112016005000A8 (enExample)
CA (1) CA2921156A1 (enExample)
RU (1) RU2016110546A (enExample)
WO (1) WO2015042029A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6346944B2 (ja) * 2013-09-19 2018-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US20210393651A1 (en) * 2018-11-09 2021-12-23 Dana-Farber Cancer Institute, Inc. Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20110003839A1 (en) * 2006-03-27 2011-01-06 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US20120088767A1 (en) * 2010-10-06 2012-04-12 Junya Qu Benzimidazole derivatives as pi3 kinase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564223A (en) * 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
AU2007212447B2 (en) * 2006-02-03 2013-02-21 Imclone Llc IGF-IR antagonists as adjuvants for treatment of prostate cancer
RU2554081C2 (ru) * 2010-02-24 2015-06-27 Медивэйшн Простейт Терапьютикс, Инк. Способ синтеза соединений диарилтиогидантоина и диарилгидантоина
WO2012119559A1 (en) * 2011-03-10 2012-09-13 Suzhou Kintor Pharmaceuticals,Inc. Androgen receptor antagonists and uses thereof
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
US20150342957A1 (en) * 2013-01-09 2015-12-03 Glaxosmithkline Intellectual Property (No.2) Limited Combination
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
JP6346944B2 (ja) * 2013-09-19 2018-06-20 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 組み合わせ薬物療法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20110003839A1 (en) * 2006-03-27 2011-01-06 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US20120088767A1 (en) * 2010-10-06 2012-04-12 Junya Qu Benzimidazole derivatives as pi3 kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOFFMAN-CENSITS, J. and FU, M. "Chemotherapy and targeted therapies: are we making progress in castrate-resistant prostate cancer" Seminars in Oncology (June 2013) vol. 40, no. 3, pages 361-374 *

Also Published As

Publication number Publication date
JP6563558B2 (ja) 2019-08-21
AU2014321456A1 (en) 2016-03-10
CN105530934A (zh) 2016-04-27
RU2016110546A (ru) 2017-10-24
WO2015042029A1 (en) 2015-03-26
JP6346944B2 (ja) 2018-06-20
JP2019196391A (ja) 2019-11-14
JP2016530208A (ja) 2016-09-29
RU2016110546A3 (enExample) 2018-03-20
US20160228446A1 (en) 2016-08-11
EP3046556A4 (en) 2017-04-26
CA2921156A1 (en) 2015-03-26
BR112016005000A8 (pt) 2018-01-23
KR20160055911A (ko) 2016-05-18
EP3046556A1 (en) 2016-07-27
JP2018158930A (ja) 2018-10-11

Similar Documents

Publication Publication Date Title
AU2010306653B2 (en) Combination
US20160367662A1 (en) Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
US20150273057A1 (en) Combination
US20180344699A1 (en) Enzalutamide in combination with afuresertib for the treatment of cancer
JP6563558B2 (ja) 組み合わせ薬物療法
EP4265300B1 (en) Composition comprising a 17 a-hydroxylase/c17,20 lyase (cyp17a1) inhibitor and an akt inhibitor
US20170348329A1 (en) Combination Drug Therapy
AU2015228475B2 (en) Combination comprising a BTK inhibitor and an AKT inhibitor
WO2014158467A1 (en) Combination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired